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Abstract 
With an onset under the age of three, autism spectrum disorders (ASD) are now 
understood as diseases arising from pre- and/or early post-natal brain developmental 
anomalies and/or early brain insults. In order to unveil the molecular mechanisms at 
play during the misshaping of the developing brain, we chose to study cells that are 
representative of the very early stages of ontogenesis, namely stem cells. Here, we report 
on MOCOS, an enzyme involved in purine metabolism (Mendel and Kruse, 2012), as a 
newly identified player in ASD. We found in adult nasal olfactory stem cells of 11 adults 
with ASD that MOCOS is downregulated in most of them when compared to 11 age- 
and gender-matched control adults having no neuropsychiatric disorders. Genetic 
approaches using in vivo and in vitro engineered models converge to indicate that 
altered expression of MOCOS results in neurotransmission and synaptic defects. 
Furthermore, we found that MOCOS misexpression induces increased oxidative stress 
sensitivity. Our results demonstrate that altered MOCOS expression is likely to impact 
on neurodevelopment and neurotransmission, and may explain comorbid conditions, 
including gastro-intestinal disorders. We anticipate our discovery to be a fresh starting 
point for the study on the roles of MOCOS in brain development and its functional 
implications in ASD clinical symptoms. Moreover, our study suggests the possible 
development of new diagnostic tests based on MOCOS expression, and paves the way 
for drug screening targeting MOCOS and/or the purine metabolism to ultimately 
develop novel treatments in ASD.    
Introduction 
 
 Autism spectrum disorders (ASD) are complex neurodevelopmental diseases arising 
from multifactorial genetic, epigenetic and environmental origins (Gepner and Feron, 2009; 
Lai et al., 2014; Levy et al., 2009; Weintraub, 2011). Systems-level connectivity features 
(Rubenstein, 2010) and plausible neuroanatomical (Travers et al., 2012), cellular (Kern and 
Jones, 2006; Zeidan-Chulia et al., 2014), and molecular (Geschwind, 2011) underpinnings of 
ASD have been highlighted. Although hundreds of susceptibility genes have been identified, 
being generally involved in neurobiological functions such as neurogenesis, synaptogenesis 
and neurotransmission (Berg and Geschwind, 2012), collectively they account for 10-20% of 
ASD cases at most (Abrahams and Geschwind, 2008). Accordingly, discovering common 
genetic traits being more representative of ASD population becomes a priority for early 
diagnoses(Walsh et al., 2011), investigation of ASD physiopathology and identification of 
new therapeutic targets.  
ASD-associated profiles are underpinned by atypical neural development often 
accompanied by epilepsy, gastrointestinal disorders and other comorbid disorders(Lai et al., 
2014). Despite numerous studies, the etiopathology as well as the physiopathogeny of these 
disorders remain largely elusive. Up to date, genetic studies on ASD have mainly used 
cellular material that, even though being sufficient for mutagenic studies, might be irrelevant 
to identify gene misexpression during development. In order to seek for novel candidates at 
play in ASD, we chose to study cells that are representative of early stages of ontogenesis. To 
this end, we decided to use human nasal olfactory stem cells (OSCs) displaying multipotent 
properties(Murrell et al., 2005),(Delorme et al., 2010) and proved to be useful for 
transcriptomic analyses in the context of brain disorders(Boone et al., 2010; Matigian et al., 
2010).  
Our study is based on a relatively homogeneous cohort of nine adults with severe 
autism and low to very low developmental abilities, plus two adults with mild or moderate 
autism and no or mild cognitive abilities (Asperger syndrome or high-functioning autism), 
paired with 11 age- and gender-matched control individuals. We first chose a non hypothesis-
driven approach and looked for transcriptome anomalies, using pangenomic cDNA 
microarrays. We observed a dysregulated expression of genes already associated to ASD. 
However, for the very first time, we identified a new candidate gene, the MOlybdenum 
COfactor Sulfurase (Mocos). Since next to nothing was known about this gene, we decided to 
assess its roles during the development of the nervous system, via C. elegans, an animal 
model widely used in studies focused on genetic and molecular anomalies in the developing 
brain. We found that the genetic ablation of Mocos induced abnormal morphologies in some 
neuronal populations and an alteration of the response to various stresses.. Then, we moved 
back to human cells and looked at their capacity to respond to a stressful situation. We also 
generated human induced pluripotent cells (iPS) in which the gene Mocos was partially 
knocked down and assessed their capacity to create synapses when differentiated into 
neurons. 
 
Materials and methods 
 
Participants  
A complete written and oral information on the goal and procedure of this research was given 
to the participants or their legal tutors, and a signed informed consent was obtained from all 
of them prior to their involvement in the study. All procedures were approved by the local 
ethical committee (Comité de Protection des Personnes, files #205016 and #205017) of 
Marseille.  
Patients with ASD (n=11) were recruited in three public hospital units (Valvert Hospital, 
Marseille; Montperrin Hospital, Aix-en-Provence; Edouard Toulouse Hospital, Marseille), in 
two socio-medical private units (Foyer d’accueil médicalisé,  Pélissanne; Service 
d’accompagnement medico-social pour adultes autistes, Salon de Provence), and through a 
specialized ASD diagnosis consultation (Montperrin Hospital, Aix–en-Provence). The 
patients were diagnosed according to ICD-10 (World Health Organization, 1993) and DSM-5 
(American psychiatric association, 2013) criteria for pervasive developmental disorders and 
autism spectrum disorders, respectively. Control patients were recruited to match the age and 
gender of each ASD patient that was endorsed in the cohort. None of the healthy controls was 
neither presenting a neuropsychiatric disorder nor taking medication. Demographics of the 
cohort is summarised in supplementary Tables 1 and 2. Details on, risk factors, comorbidity, 
medication and MRI data of ASD patients of the cohort are given in supplementary Tables 3-
5. 
Nasal biopsies 
Nasal biopsies were performed by an ENT surgeon as we previously described(Girard et al., 
2011). For ASD patients, the tissue was biopsied right before a brain magnetic resonance 
imaging (MRI) examination, requiring a general anesthesia in all of them. Control 
participants were biopsied during an ENT surgery. 
Cell culture 
For nasal olfactory stem cells (OSCs) culture, fresh biopsies were immediately placed in 
growth medium containing DMEM/Ham F12 supplemented with 10% Fetal Bovine Serum 
(FBS) and 100 units/mL of penicillin and 100 µg/mL of streptomycin (Invitrogen). OSCs 
were purified from the lamina propria and cultivated as described before(Delorme et al., 
2010; Girard et al., 2011). All experiments using OSCs were performed with cells at a low 
passage number (P1 to P5). When the two cohorts were compared, the same passage number 
was used.  
For induced pluripotent stem cells (iPSCs) culture, we used previously established and 
characterized iPSC lines(Xia et al., 2013) derived from human fibroblasts by using an 
episomal-based reprogramming strategy. In feeder-free conditions, human iPSCs were 
cultured in chemically defined growth media, mTeSR (StemCell technologies), on growth-
factor-reduced Matrigel (BD Biosciences)-coated plates. Briefly, 70–80% confluent human 
ESCs/iPSCs were treated with dispase (Invitrogen) for 7 min at 37C and the colonies were 
dispersed to small clusters and lifted carefully using a 5 ml glass pipette, at a ratio of ∼1:4. 
Prior to the generation of MOCOS+/- iPSCs, iPSCs were transferred onto irradiated 
neomycin-resistant MEFs and cultured in WiCell media composed of DMEM/F12 
(Invitrogen), 20% Knockout serum replacement, 10 ng/ml bFGF, 1 mM GlutaMax, 0.1 mM 
non-essential amino acids and 55 μM β-mercaptoethanol. After 2 to 3 days of culture in these 
conditions, MEFs-conditioned medium was used instead of fresh WiCell. 
Mytomycin-C treated Mouse Embryonic Fibroblasts (MEFs, Chemicon) and irradiated 
neomycin-resistant MEFs (Applied Stem Cell) were plated onto gelatin (0.1%)-coated plate 
in a medium containing DMEM supplemented with 10% FBS and 1% non-essential amino 
acids. For our experimental conditions, MEFs were plated at 200,000 cells/well of a 6-well 
plate or 1x106 cells/100mm dish. MEFs-conditioned medium was prepared by replacing the 
MEF medium of Mytomycin-C treated MEFs with WiCell media, 24hours after MEFs 
thawing. The conditioned media was collected and filtered (0.2 µm) every 24hours for up to 
5 days of MEFs culture. All cell lines were maintained in an incubator (37C, 5% CO2) with 
media changes every day (iPSCs, MEFs) or every second day (OSCs). 
Primary cultures of cortical neurons were prepared from C57/Bl6 mice embryos according to 
the guidelines of the Ethics Committee of the Medical Faculty of Marseille and conform to 
National and European regulations (EU directive Nu 86/609). Pregnant mice were deeply 
anesthetised with sodium pentobarbital (Ceva Santé Animale) prior to remove E16 embryos 
from their placenta. Embryos were quickly removed and placed into cold Hank’s balanced 
salt solution (HBSS, Life Technologies) containing 5 U/ml penicillin/streptomycin (Life 
Technologies). Embryos were decapitated and cerebral cortices were dissected prior to be 
enzymatically dissociated for 10 min at 37°C in HBSS containing 0.1% trypsine and 10 
mg/ml DNase I (Sigma-Aldrich, Saint Quentin Fallavier, France). The enzymatic reaction 
was stopped with DMEM containing 10% Fetal calf serum (FCS, Life Technologies) and 5 
U/ml penicillin/streptomycin (Life Technologies). Further mechanical dissociation was 
carried out by trituration through a Pasteur pipette. After centrifugation at 1,250 rpm during 5 
min at room temperature, cell pellets were resuspended in plating medium containing DMEM 
supplemented with 10% FCS and 5 U/ml penicillin/streptomycin. Cell suspension was plated 
at a seeding density of 1.5x105 cells/well onto 12 mm diameter glass coverslips precoated 
with 1 mg/ml poly-L-Lysine (Sigma-Aldrich) in filtered-borate buffer pH 8.5, and were 
incubated at 37°C in a humidified chamber containing 5% CO2. After 1 hour, the plating 
medium was replaced by a serum free defined medium containing Neurobasal (Life 
Technologies) supplemented with 2% B27 supplement (Life Technologies), 5 U/ml 
penicillin/ streptomycin, 2.5 mM Glutamine (Life Technologies). Neurons were allowed to 
grow for 4 days (37°C, 5% CO2). Then, cells were fixed for 20 min with Antigenfix solution 
(Diapath) at room temperature. After washing in PBS 1X, cells were stocked at 4°C until 
being processed for immunostaining. 
Hybridization on pangenomic cDNA arrays 
In order to limit biases, OSCs from the 22 individuals were collected by the same operator, 
under the same conditions: i.e. identical culture medium, level of confluency (100%) and 
equal passaging (P3). In addition, in order to avoid any circadian rhythm-related variations in 
gene expression, cells were collected at the same time of the day. Total RNA was then 
isolated using RNeasy Mini kit (Qiagen), according to the manufacturer’s instructions. RNA 
concentration was determined using a nanodrop 2000 spectrophotometer (Thermo Scientific) 
and RNA integrity assessed on an Agilent 2100 Bioanalyzer. Sample amplification, labeling, 
and hybridization were performed in line with the Agilent two-color microarray-base analysis 
(low input quick amp labeling) protocol (Agilent Technologies). In brief, total RNA was 
reverse transcribed into cDNA using the T7 promoter primer. The reaction intending to 
synthesize cyanine-3 labeled cRNA from cDNA was performed in a solution containing 
dNTP mix, T7 RNA polymerase and cyanine 3-dCTP and then incubated at 40°C for 2 hours. 
Labeled cRNA was purified and fragmented before hybridization on Agilent whole human 
genome Expression Arrays, containing 62,975 oligonucleotide probes, at 65°C for 17 hours. 
Raw microarray signals were scanned and extracted using Agilent Feature Extraction 
Software (Agilent Technologies). AgiND R package was used for quality control and 
normalization. Quantile methods and a background correction were applied for data 
normalization. Microarray data have been deposited in NCBI-GEO under the accession 
number GSE63524. 
Microarray data analysis  
Biological interpretation of the data was performed using two bioinformatic softwares: 
Ingenuity Pathway Analysis (IPA, Ingenuity Systems; http://www.ingenuity.com/) and MeV 
(MultiExperiment Viewer Version 4.3; http://mev.tm4.org). The first program was used to 
identify biological functions and upstream regulators enriched in the lists of differentially 
expressed genes associated to the psychiatric condition. Right-tailed Fisher’s exact test was 
used to calculate a p-value determining the top statistically significant biological functions 
assigned to the data set. The second program allowed us to draw a volcano plot 
representation, enabling a visual identification of genes that display statistically significant 
changes. For both analyses, we considered only genes with an absolute fold change of 1.5 
and a p value <0.05. 
RNA isolation and Real-time PCR analysis  
RNA samples extracted from OSCs were tested with qRT-PCR in order to quantify the 
expression of MOCOS. Total RNA (1 μg) was subjected to reverse transcription reaction to 
synthetize cDNA using oligo dT, RNase Out and M-MLV RT enzyme (Invitrogen, 
ThermoFisher Scientific, Villebon sur Yvette, France) according to the manufacturer’s 
instructions. Real time qPCR experiments were carried out with the 7500 Fast real-Time PCR 
system (Applied Biosystems, ThermoFisher Scientific, Villebon sur Yvette, France), using 
TaqMan® Fast Universal PCR Master Mix (2X) and two TaqMan® Gene Expression Assays 
(MOCOS: Hs00215742_m1; TBP: Hs00920495_m1). Experiments used 7.5 ng of previously 
prepared cDNA and samples were run in triplicates. Relative expression levels were 
determined according to the ΔΔCt method where the expression level of the mRNA of 
interest is given by 2-ΔΔCT where ΔΔCT = ΔCT target mRNA − ΔCT reference mRNA 
(TBP) in the same sample.  
Western blot analysis 
OSCs were lysed and homogenized in RIPA buffer (Sigma-Aldrich) containing a cocktail of 
protease inhibitors (1/100, Calbiochem). Protein concentrations were determined by the DC 
protein assay (Biorad, Hercule, CA) according to the manufacturer's protocol. For all 
conditions, Western blot were performed from 20 µg of proteins, using SDS-PAGE 10% 
polyacrylamide resolving gels (MiniBlot system, Bio-Rad) and then transferred onto 
Hybond-ECL nitrocellulose membranes (Amersham Biosciences, Buckinghamshire, UK). 
Before blocking, the blots were stained with ponceau red to visualize transfer efficiency. 
Protein-containing membrane was blocked using PBS-5% skim milk for 2 h at room 
temperature and then incubated overnight at 4°C with a rabbit anti-MOCOS antibody (Novus 
biologicals NBP2-14243, 95kDa, 1/100) and a mouse anti-GAPDH antibody (Millipore 
MAB374, 37k Da, 1/5000) in PBS-5% skim milk. After incubation with primary antibodies, 
blots were washed three times for 10 min with a solution containing PBS and 0.2% Tween-20 
(PBS-T), incubated with goat anti-rabbit-HRP (1/1000, Jackson Immunoresearch) or goat 
anti-mouse-HRP (1/5000, Jackson ImmunoResearch) in PBS-5% skim milk for 2 hours at RT, 
and washed three times for 10 min each with PBS-T. Finally, proteins were detected using a 
chemiluminescence kit (Amersham RPN2209). Chemiluminescent signals were projected on 
X-ray film and digitalized, and the signals were quantified using NIH ImageJ software 
(version 1.43). 
Animals 
C. elegans strains were maintained at 20°C under standard growth conditions. Strains used in 
these studies include: N2 (wild type), mocs-1(tm3708), mocs-1(ok3439), ric-3(md158), eri-
1(mg366), mev-1(kn1), arls37 [Pmyo-3::ssGFP], nuIs183 [unc-29-nlp-21::YFP](Sieburth et 
al., 2007) and VAP1::RFP (generous gift of L. Bianchi, University of Miami). The modified 
WRM0612B_E02 fosmid was obtained from the TransgeneOme project. In this vector, the 
GFP coding sequence was fused to the 3′ end of mocs-1(Sarov et al., 2012). Wild type 
transgenic animals were selected after bombardment of unc-119(ed3) mutants. The tm3708 
mutant contains a 621 base pair deletion that removes intron 1 and part of exon 2 (See Fig. 
3a). The tm3708 deletion was predicted to represent a null allele because the mutation is 
generating a premature amber stop codon after only 10% of the coding region. The ok3439 
deletion removes part of exon 2 and all subsequent exons up to exon 5 (See Fig. 3a). This 
mutant displays an in frame deletion of the L-cysteine desulfurase domain: ok3439 is 
predicted to be devoid of 163 amino acids in a region known to bind the PLP cofactor and 
mobilize sulfur from L-cysteine. Thus ok3439 deletion mutants are supposed to be free of 
their cysteine desulfurase activity while the MOSC domain remains intact. 
C57/Bl6 mice (8-week old) were used to evaluate the expression of MOCOS in various 
organs as well as to establish primary cultures of neurons. All murine experiments were 
conducted according to the guidelines of the Ethics Committee of the Medical Faculty of 
Marseille and conform to National and European regulations (EU directive Nu 86/609). 
Animal were housed in air-flow racks on a restricted access area and maintained on a 12 hour 
light/dark cycle at a constant temperature (22 ±1°C). 
Paraquat assay 
For paraquat sensitivity during development, adult animals were placed on plates containing 
increasing concentrations of paraquat (0.15, 0.22, 0.44, 0.66 and 4 mM), allowed to lay eggs 
for 6 hours and then removed. Over a 4-day period, the proportion of animals at every 
development stage (L1-L4) progeny was scored. The total number of worms that survived 
after exposure to 4 mM of paraquat was assessed. To test the sensitivity of adult worms to 
oxidative stress, young adults (day1) were transferred to fresh plates containing 4 mM of 
paraquat. The total number of worms that survived was counted after 24, 48 and 72 hours.  
RNAi procedures 
Bacteria expressing dsRNA directed against R03A10.3 and L4440 were part of a C. elegans 
RNAi library expressed in E. coli (Geneservice, Cambridge, UK). RNAi was delivered by 
feeding as previously described(Kamath et al., 2001). In brief, L4 hermaphrodites were 
placed on RNAi feeding plates. After 4 days, F1 progeny were transferred either to plates 
filled with nematode growth medium (NGM) agar supplemented with 20 mM paraquat or to 
control unsupplemented NGM plates.  
 
ROS assay in OSCs 
Generation of intracellular reactive oxygen species (ROS) in human OSCs was measured by 
staining with CellROX® Green Reagent (Molecular Probes) according to the manufacturer’s 
instructions. In brief, OSCs from ASD and control patients were seeded in 96-well plates and 
maintained in DMEM/HAM culture medium supplemented with insulin, transferrin, selenium 
(ITS-X, 1%; Invitrogen) for 24h.  CellROX® Green Reagent (5 µM) was added to the culture 
medium for 30 minutes at 37°C, either at baseline or one hour after addition of staurosporine 
(1 M) in the culture medium. After washing, fluorescence was measured with a Beckman 
Coulter plate reader. Experiments were performed in triplicate.  
Aldicarb and levamisole-induced paralysis assays 
Acute sensitivities to aldicarb and levamisole were assayed in paralysis assays as previously 
described(Mahoney et al., 2006). For the aldicarb assay, Thirty to forty young adult animals 
were transferred to NGM agar plates containing 0.25 mM aldicarb and day1 adult worms 
were scored every 30 min (moving ratio). For the levamisole-induced paralysis assay, NGM 
agar plates containing various concentrations of levamisole (0.1, 0.2, 0.5, 0.8 and 1 mM) 
were prepared 1 day prior to the assay and adult worms were tested for complete paralysis 
after 60 min of drug exposure. Animals were considered paralyzed if they failed to move 
when prodded with a platinum wire.  
Fluorescence imaging and quantitative analysis of NLP-21 and GFP containing vesicles 
Live animals were immobilized with 50 mM Na-azide in M9 buffer and NLP21::YFP or GFP 
distribution was evaluated in cholinergic motor neurons (soma and dorsal cord axons) and/or 
coelomocytes. Stacks of confocal images were obtained on an inverted microscope 
(LSM780; ZEISS) using a 63X NA 1.4 oil immersion objective. All quantitative analysis 
were performed using ImageJ software (National Institutes of Health) as described 
previously(Sieburth et al., 2007). Results are expressed as values normalized to wild type. 
For the dorsal nerve cords analysis, mean grey levels intensities were measured on maximal 
intensity projections of stacks of 5 consecutive optical slices. Individual coelomocytes and 
nerve cord neurons were imaged by 3D-stacks using the same final magnification. Mean 
vesicular diameters and mean intensities were measured on the optical slice passing through 
the largest part of each individual vesicle using a 3D-threshold and particle detection.  
Construction of MOCOS gene correction TALENs and donor vectors 
We decided to designed two pairs of TALENs. TALENS target sites 1 and 2 were identified 
using the TAL effector-Nucleotide Targeter (TALE-NT) program(Christian et al., 2010). 
Chosen targets had a T at the -1 position and showed the best score. TALENs recognizing the 
target sites were constructed using the Golden Gate Assembly method with the TALE 
Toolbox kit from Addgene (cat#1000000019)(Zhang et al., 2011). The constructed TALEN 
pairs targeting exon 3 and intron 3 of the MOCOS gene were named as MOCOS1-5’/ 
MOCOS1-3’ and MOCOS2-5’/ MOCOS2-3’, respectively. The MOCOS-donor vector was 
constructed by In-Fusion HD (Clontech). In brief, an FRT-PGK-EM7-neo-bpA-FRT 
fragment was subcloned into the EcoRI (New England Biolabs) and BamHI (New England 
Biolabs) sites of the pUC19 vector  (New England Biolabs) together with 0.9 kb of 5’ 
homology and 0.8 kb of 3’ homology arms, which were amplified by PCR of genomic DNA 
from integration-free iPSCs(Xia et al., 2013) with the following primers (5’ homology  arm; 
5’- GACGGCCAGTGAATTCTGTCATCAGTGGCATTTATTTGCAGCACAAC-3’ and 5’-
TTTTGCTCCCTTCCTGGTGTCCT-3’, 3’ homology  arm;  5’-
TTACCTCACCGACAGCCACACCTCCGTA-3’ and 5’- 
CGACTCTAGAGGATCCGGCCTGGTAGCTCACCCTCCTTACCC) using Q5 Hot Start 
High-Fidelity DNA Polymerase (New England Biolabs) following manufacturer’s 
instructions. 
 
Surveyor assay 
To examine the efficacy of the generated TALENs, we performed Surveyor assay in HEK293 
cells as previously described(Sanjana et al., 2012). 
Generation of the MOCOS gene-knockout human iPSCs. 
To disrupt MOCOS gene, integration-free iPSCs were chosen as host cells(Xia et al., 2013). 
For generation of the heterozygous MOCOS knockout iPSCs, 1.5 x 107 feeder-free cultured 
iPSCs were dissociated by AccuMax (Innovative Cell Technologies) and resuspended in 1ml 
of Mouse embryonic fibroblasts (MEF)-conditioned medium containing 10 mM ROCK 
inhibitor Y-27632 (Biomol Inc.). Cells were electroporated with 8 mg of TALEN expression 
vectors and 32 mg of donor vectors and were plated onto 100 mm dishes precoated with 1 x 
106 irradiated neomycin-resistant MEFs (Applied Stem Cell). Two days after electroporation, 
G418 (50 mg/ml; Invitrogen) was added to the medium to start positive selection. After 18 
days, G418-resistant clones were transferred to 96-well plates and expanded for further 
characterization. Gene-targeted clones were determined by PCR of genomic DNA from drug-
resistant clones with the following primers (P1: 5’-
TGGCTCAGGGACAGACACACAGGTTACTACCAG-3’ and P4: 5’-
AGCCACCATTTTCAGCCTTGACACACTCGAC-3;) using PrimeSTAR GXL DNA 
Polymerase (TAKARA) following manufacture’s protocol (see Fig. 4g and Supplementary 
Fig. 3). To remove the neomycin-resistance cassette, we generated a pCAG-Flpo-2A-puro 
vector, which, under control of a CAG promoter, expresses the genes for Flpo 
recombinase(Raymond and Soriano, 2007), and puromycin N-acetyltransferase (puro). 
MOCOS heterozygous knockout iPSCs cultured on Matrigel were transfected with pCAG-
Flpo-2A-puro vector using FuGENE HD (Promega). Two days after transfection, puromycin 
(1 μg/ml; Invitrogen) was added to the medium to enrich Flpo recombinase expressing cells. 
Two days later, puromycin was withdrawn, and after about 10 days, cells were individualized 
and plated onto MEF feeder cells at a density of 300-3000 cells / 75 cm2 in the presence of 
10 μM Y-27632 (Biomol Inc.). After 2 weeks, the emerging colonies were hand picked and 
expanded. Removal of the neomycin-resistance cassette was verified by PCR with the same 
primers (5’-TGGCTCAGGGACAGACACACAGGTTACTACCAG-3’ and 5’-
AGCCACCATTTTCAGCCTTGACACACTCGAC-3) using PrimeSTAR GXL DNA 
Polymerase following manufacture’s protocol (see Supplementary Fig. 3). The determined 
heterozygous knockout clones (MOCOS+/-) were used in another round of gene knockout to 
try top generate homozygous knockout cells. For this, we repeated the same steps. However, 
no biallelic MOCOS knockout clones (MOCOS-/-) were ever generated after three attempts. 
Neuronal differentiation from hiPSCs  
First we derived neural stem cells (NSCs) from iPSC (MOCOS+/+ and MOCOS+/-) as 
described elsewhere(Liu et al., 2012) with slight modifications. In brief, feeder-free culture of 
human iPSCs were passaged onto matrigel-coated plate at about 20% confluence. Culture 
medium was then switched to Neural Induction Medium 1 (NIM-1: 50% Advanced 
DMEM/F12 (invitrogen), 50% Neurobasal (invitrogen), 1x N2 (invitrogen), 1x B27 
(invitrogen), 2 mM GlutaMAX (Invitrogen) and 10 ng/mL hLIF (Prospec), 4 μM 
CHIR99021 (Reagents Direct), 3 μM SB431542 (Stemgent), 2 μM Dorsomorphin (Sigma), 
and 0.1 μM Compound E (EMD Chemicals Inc.). Cells were treated with NIM-1 for 2 days, 
and then switched to Neural Induction Medium 2 (NIM-2: 50% Advanced DMEM/F12, 50% 
Neurobasal, 1x N2, 1x B27, 2 mM GlutaMAX, 10 ng/mL hLIF, 4 μM CHIR99021, 3 μM 
SB431542 and 0.1 μM Compound E) for another 5 days. The cultures were then split onto 
matrigel-coated plates with Accumax (Innovative Cell Technologies) and cultured in Neural 
Stem cell Maintenance Medium (NSMM) containing 50% Advanced DMEM/F12, 50% 
Neurobasal, 1x N2, 1x B27, 2 mM GlutaMAX, 10 ng/mL hLIF, 3 μM CHIR99021, and 2 μM 
SB431542. NSC culture. NSCs were maintained on Matrigel in NSMM. NSCs were passaged 
once reaching 80% confluency using Accumax and seeded at about 20% confluency 
(Cytoone). Medium was changed every day. For the initial 6 passages, NSCs were treated 
with 10 μM Y-27632 (Biomol Inc.) during splitting. From passage 7, NSCs were induced to 
differentiate into neurons.  
For neuronal differentiation, human NSCs were plated onto poly-ornithine (Sigma) and 
laminin coated dishes in NSMM. After 2 to 3 days, medium was switched to Neurobasal 
medium (Invitrogen) supplemented withN2 (0.5X), B27 (1X) and FGF2 (10 ng/ml, 
Preprotech). Four days later, FGF2 was withdrawn from the medium, and after another 4 
days, medium was switched to Neurobasal media supplemented with B27 (1X) and brain 
derived neurotrophic factor (BDNF, 20 ng/ml, R&D Systems). Differentiated cells were 
maintained up to 4 weeks after FGF2 withdrawal prior to perform immunocytological 
analyses. 
Immunochemistry 
For mouse tissues staining, adult mice (n=3) were transcardially perfused with 20 ml ice-cold 
saline (0.9‰ NaCl), followed by 50 ml ice-cold 4% paraformaldehyde in phosphate buffered 
saline (PBS), pH 7.2, and their brain, kidneys, liver and gut were dissected and post-fixed for 
2 h in 4% Paraformaldehyde. Then, each organ was rinsed and cryoprotected in 0.32M 
sucrose prior to be processed for cryosectioning. Each organ was embedded with cryostat 
mounting medium (Cryomount), cryo-sectioned at 20 m thickness (Leica CM30505), thaw-
mounted on pre-coated slides (Superfrost Plus, Thermo Scientific) and stored at −80C until 
use. Sections were air-dried for one hour before being processed for immunohistochemistry.  
For immunocytostaining, cells to be stained were prepared on glass cover slips (coated with 
the appropriate substrate when necessary). Cells were fixed in 4% paraformaldehyde for 12 
minutes at room temperature and washed at least 3 times in PBS prior to be processed for 
immunocytochemistry.  
Tissue sections/cells were first incubated for 1 hour at room temperature (RT) with a 
blocking buffer containing 3% BSA, 5% appropriate serum and 0.1% Triton X-100 in PBS. 
Then, tissue sections/cells were incubated for 1 hour at RT(or overnight at 4°C) with the 
following primary antibodies diluted in blocking solution: rabbit polyclonal anti-MOCOS 
(1:100 for cells and 1:20 for tissue sections; Novus biologicals NBP2-14243), chicken 
polyclonal anti-MAP2 (1:300; Abcam, Ab5392), mouse monoclonal anti-TUJ-1 (1:500; 
COVANCE MMS-435P); rabbit polyclonal anti-SYNAPSIN (1:250; Millipore AB1543P ). 
After three washes in PBS, tissue sections/cells were incubated with either Alexa 488 or 
Alexa 594 or Alexa 568 fluorescent secondary antibodies (Molecular Probes) diluted at 1:500 
in PBS for 1 hour at RT; and counterstained with DAPI prior to be washed and mounted. 
Tissue sections/cells were examined using a Zeiss LSM 710 Laser Scanning Confocal 
Microscope (Zeiss).  
Statistical evaluation 
Statistical analyses were performed by using standard unpaired Student t-tests (two-tailed, 
95% confidence intervals) or one-way ANOVA, and were carried out using Prism Software 
(GraphPad) or Excel software (Microsoft). For microarray data analyses, Right-tailed 
Fisher’s exact test was used to calculate a p-value determining the top statistically significant 
biological functions assigned to the data set. All data are presented as mean±s.d. and 
represent a minimum of three independent experiments with at least three technical replicates 
except when otherwise indicated. A value of P<0.05 was considered significant.  
 
 
Results 
We first established the transcriptome profiles of OSCs isolated from nasal 
biopsies(Girard et al., 2011) of 11 patients diagnosed with ASD and 11 age- and gender-
matched control individuals (Supplementary Tables 1-5). Gene microarray analysis identified 
156 genes that were differentially expressed in at least one ASD patient (Supplementary 
Table 6), of which 31 were dysregulated in more than a third of the cohort (Supplementary 
Table 6, in red). Notably, 9 out of these 156 genes – ADAM23, CADM1, FOS, FOSB, JAG1, 
MEST, OXTR, SFRP1 and XIST – have been previously associated to ASD(Parker et al., 
2014). Ingenuity Pathway Analysis (IPA) on the pool of differentially regulated genes 
identified developmental disorders and gastrointestinal diseases as two of the most 
represented categories associated with these genes (Supplementary Table 7). Furthermore, 
IPA predictive analysis highlighted that, among the main upstream regulators of the 
differentially expressed genes, three – TNF, IFNG and IL1B – are associated with 
inflammation (Supplementary Table 7), a functional process widely associated with 
ASD(Chez et al., 2007; Depino, 2013). In addition, gene cluster analysis revealed that all 
patients were affected by a partial dysregulation of the TGF-β/Wnt pathways (Fig. 1a and 
Supplementary Table 8), known to play an important role in ASD(Ashwood et al., 2008; 
Kalkman, 2012). Second in line among the most affected pathways, purine metabolism 
appeared largely disturbed with the misexpression of at least one of two enzyme-coding 
genes, MOCOS and AOX1, in 10 out of 11 patients (Supplementary Table 8). Whereas AOX1 
was found differentially expressed in 3 out of 11 patients, its pattern of expression was 
heterogeneous when compared to the subtle but robust MOCOS downregulation displayed by 
~80% (8/11) of the patients composing our cohort (Fig. 1b,c), which is amazing when 
considering that hundreds of susceptibility genes account for 10-20% of ASD cases at most 
(Abrahams and Geschwind, 2008). Importantly, MOCOS downregulation in ASD patients’ 
OSCs was confirmed at both the RNA and protein levels (Fig. 1c-f). Interestingly, metabolic 
disorders of purine metabolism have been described to affect the nervous system and able to 
induce autistic features(Manzi et al., 2008; Page and Coleman, 2000). Accordingly, we 
decided to focus on MOCOS, an enzyme acting upstream in the purine catabolism pathway, 
and investigate its putative role in ASD.  
The fact that MOCOS adds a sulfur on the molybdenum cofactor and turn XDH into 
its active form to catalyse the oxidation of hypoxanthine to xanthine and, further down, the 
oxidation of xanthine to uric acid, led us to retrospectively investigate whether our patients 
suffered from xanthinuria(Mendel and Kruse, 2012; Yamamoto et al., 2003). In addition, and 
because creatinine and ferritin are often associated with uric acid production, we also 
assessed their expression in the blood and the urine. Except in one patient that displayed a 
high level of xanthine, our analyses did not reveal any direct correlation between these three 
measurements (Supplementary Table 9). These results led us to propose that MOCOS 
misexpression might affect other functions and we decided to investigate whether it could 
play a role in brain functions. 
We first sought to look at the dynamic expression of MOCOS in the brain. Using the 
Allen Brain Atlas tool, we found that MOCOS is expressed in numerous areas of the 
developing and adult human brain. Confirming the expression pattern suspected by 
transcriptomic analyses in human, adult mouse brain tissue analysis confirmed the presence 
of MOCOS, at the protein level, in multiple brain areas such as the hippocampus, the cortex, 
the cerebellum and the brainstem (Fig. 2a and Supplementary Fig. 1a). Furthermore, MOCOS 
was readily detected in MAP2+ murine neurons in vitro and in vivo (Fig. 2b-d and 
Supplementary Fig. 1a). In parallel, we found that MOCOS is expressed in other tissues such 
as the intestine, the kidney and the liver (Fig. 2e,f and Supplementary Fig.1b). Since MOCOS 
is a gene highly conserved across species, we additionally analysed its expression in 
Caenorhabditis elegans by using a transgenic strain in which the GFP coding sequence was 
fused to the 3′ end of the orthologous gene mocs-1(Sarov et al., 2012). We observed GFP 
expression as early as the 8-cell stage of the intestine and throughout the larval and adult life 
of the animal in the cytoplasm of cells in the intestine as well as in the head (Fig. 2g). 
Regarding the latter, mocs-1 reporter expression was detected in sheath and socket glial cells 
(Fig. 2g and Supplementary Fig. 1c). Altogether, these data suggest that throughout evolution, 
MOCOS plays an important role in development and adult life. Importantly, the 
multicellular/multiorgan distribution of MOCOS fits with the search of a pleiotropic gene 
that could explain complex disorders such as ASD.  
In order to investigate whether altered expression of MOCOS correlates with ASD-
associated phenotypes, we used two independent C.elegans strains mutant for mocs-1 and 
bearing a nonsense mutation (tm3708) or a frameshit mutation (ok3439) (Fig. 3a). Several 
studies having reported a greater oxidative stress in children with autism (James et al., 2006; 
McGinnis, 2004), we first assessed the sensitivity of mocs-1 mutants to paraquat, an oxygen 
radical-generating agent. Whereas development was slowed down in all worms exposed to 
0.22 mM of paraquat, 82% and 52% of tm3708 and ok3439 mutants, respectively, reached 
the L4 larval stage when compared with wild type animals (Fig. 3b), demonstrating an 
increased sensitivity to oxidative stress. Interestingly, the observed effects were dose-
dependent as larval development was blocked at the L2/L3 stages in mocs-1 mutants treated 
with higher concentrations (≥ 0.44 mM), and led to a significantly lower survival rate in 
tm3708 (12%) and ok3439 (0%) mutants comparatively to wild type (98.5%) animals 
exposed at 4 mM of paraquat (Fig. 3b,c). Confirming the role and specificity of mocs-1 in 
response to paraquat, similar results were obtained with eri-1 animals fed with an RNAi 
against R03A10.3, the mocs-1 predicted gene (Fig. 3d). Similarly, we observed that exposure 
to paraquat at an adult stage strongly decreases the viability of mocs-1 mutants as well as eri-
1 animals fed with R03A10.3 RNAi when compared with their respective controls (Fig. 3e,f). 
Then, we evaluated whether a similar feature could be observed in patients’ OSCs displaying 
MOCOS downregulation. Validating further our initial observations in worms, those cells 
revealed a higher production of reactive oxygen species (ROS), at baseline and one hour after 
staurosporine treatment, when compared with their respective controls (Fig. 3g). Notably, this 
feature is in line with the fact that MOCOS adds a sulfur atom on the molybdenum cofactor 
of AOX1, an enzyme involved in the regulation of ROS homeostasis. Altogether, these data 
demonstrate that altered expression of MOCOS may increase sensitivity to oxidative stress, a 
feature that has been widely reported to contribute to the development and clinical 
manifestations of autism (James et al., 2006; McGinnis, 2004).  
 To date, the physiopathology of ASD is commonly accepted to be partly due to a 
defective regulation of neurotransmission (Gepner and Feron, 2009; Sudhof, 2008). 
Accordingly, we assessed synaptic function in mocs-1 mutants. To this end, we evaluated the 
synaptic transmission at the neuromuscular junction by monitoring the sensitivity of mocs-1 
mutants to the paralyzing effects of aldicarb, an acetylcholinesterase inhibitor(Mahoney et al., 
2006). We found that tm3708 and ok3439 animals were resistant to aldicarb when compared 
with N2 wild type worms (Fig. 4a). Notably, we observed similar paralytic and lethal effects 
in wild type and mocs-1 mutant worms exposed to increasing concentrations of levamisole, 
ruling out an alteration of the postsynaptic receptor function (Supplementary Fig. 2a). Next, 
we reasoned that aldicarb resistance in mocs-1 mutants could be the consequence of a 
decreased neuropeptide secretion. Accordingly, we analyzed the secretion of the YFP-tagged 
neuropeptide NLP-21 in cholinergic motor neurons. As shown in Figure 4, NLP-21 puncta 
fluorescence intensity was significantly reduced in the dorsal cord axons of tm3708 
hypomorph mutants (23.5% ± 3) when compared to wild type animals and a similar decrease 
was observed in coelomocytes (29.2% ± 8.5%) of both groups of animals (Fig. 4b,c). 
Together, these data suggested a reduced number of dense-core vesicles (DCVs) in the axons 
as well as a quantitatively reduced but functionally normal neuropeptide secretion. Further 
investigations on tm3708 mutants showed a significant accumulation of NLP-21 in the soma 
of dorsal cord neurons and demonstrated that NLP-21 was localized into larger vesicles (≥ 
0.2 µm2) when compared to control animals, suggesting that defects in neuropeptide 
packaging account for the observed phenotype (Fig. 4d-f). Of note, the observed phenotypes 
were confirmed in tm3708 mutants harboring an integrated pmyo-3::ssGFP transgene 
(Supplementary Fig. 2b-d). Interestingly, similar analyses on ok3439 neomorph mutants 
revealed no difference of NLP-21 distribution in dorsal cord neurons but a significant 
decrease number within coelomocytes (Fig. 4b-e), highlighting that ok3439 mutants have 
decreased neuropeptide secretion when compared with wild type animals. In summary, 
although the two mocs-1 mutant strains were found differentially affected, probably due to 
the nature of the mutation, our results indicate that deregulation of MOCS-1 expression may 
affect the neuropeptide secretory system.  
This finding prompted us to use induced pluripotent stem cells (iPSC) for validating the 
role of MOCOS in human neuronal cells. Using TALEN technology, we successfully derived 
four heterozygous knockout (MOCOS+/-) iPSCs lines (Fig. 4g and Supplementary Fig. 3). 
Notably, several attempts at establishing homozygous knockout (MOCOS-/-) iPSC lines failed, 
suggesting an important role of MOCOS in human cell homeostasis, at least during early 
development. To investigate whether MOCOS can play a role in neurotransmission, 
MOCOS+/- iPSCs and their respective isogenic MOCOS+/+ control lines were differentiated 
into neurons (Fig. 4h). The synaptic compartment being an important element for 
neurotransmission, we analysed the number of synaptic buttons in iPSCs-derived neurons 
(Fig. 4h). Of outmost importance, and even though we did not observe difference in their 
capacity to generate TUJ1-expressing neurons, those derived from MOCOS+/- iPSCs 
displayed a lower number of SYNAPSIN+ synaptic buttons (Fig. 4i,j). These results confirm 
that MOCOS is a newly identified molecule at play during neurodevelopment and 
neurotransmission. 
Discussion 
 Together, our results highlight MOCOS as a new candidate molecule implicated in 
ASD physiopathogeny and unveil novel biological functions associated with MOCOS, 
including roles in stress response and neurotransmission. Bearing in mind that MOCOS was 
found downregulated in most ASD patients of our cohort, the phenotypes observed in our 
cellular and animal models are of the most relevance to establish a causal link between 
MOCOS misregulation and ASD-associated clinical symptoms. Of interest, metabolic defects 
have been associated with autistic symptoms with a prevalence higher than that found in the 
general population(Manzi et al., 2008), including purine metabolism disorders(Page and 
Coleman, 2000). Furthermore, xanthines and more generally purine derivatives were found to 
have psychostimulant properties through their possible interaction with multiple receptors 
(Shi and Daly, 1999). Additionally, this is the first time that MOCOS is described as a 
putative modulator of other developmental and adult functions.  
 Among body metabolism biomarkers in ASD, and as shown in our results, oxidative 
stress indicators stand out. It has been observed that urinary antioxidants are found in smaller 
amounts in ASD patients and that their levels of production are correlated with symptom 
severity(Damodaran and Arumugam, 2011). Misexpressed molecules include, for example, 
glutathione, advanced glycation end products (AGE), superoxide dismutase and metal-
binding proteins such as transferrin (iron) and ceruloplasmin (copper)(for a recent review, 
Goldani et al, 2014). Lately, a diminished seric expression of glutathione, glutathione 
peroxidase, methionine, and cysteine has been highlighted in a meta-analysis from 29 studies 
on ASD subjects (Frustaci et al, 2012). Along this line, purines and purine-associated 
enzymes are recognised markers of oxidative stress. Reactive oxygen species (ROS) are 
generated during the production of uric acid, catalysed by xanthine oxidase and xanthine 
dehydrogenase (Schulz et al, 2011). Conversely, uric acid is nowadays recognized as a 
protective factor acting as a ROS scavenger (Waring, 2002; Nabipour et al, 2011). 
Interestingly, allopurinol, a xanthine oxidase inhibitor, was found efficient in reducing 
symptoms, especially epileptic seizures, in ASD patients displaying high levels of uric acid 
(Coleman et al, 1974). However, in our cohort, only 3 out of 10 patients exhibited an 
abnormal uric acid secretion. It can therefore be postulated that still unknown other MOCOS-
associated mechanisms play a role in the unbalanced stress response observed in ASD 
olfactory stem cells.   
 According to our results, MOCOS is also associated to neurotransmission 
abnormalities, that have previously been proved to be strongly affected in ASD(Gepner, 
Feron, 2009). It has not escaped our notice that the enzymatic nature of our candidate 
molecule fits well with the wide-ranging and unspecific neurotransmitter imbalance observed 
in ASD. As a molecule involved in the formation of dense core vesicles (DCV) and, further 
down, neurotransmitter secretion, MOCOS seems to act on the container rather the content, 
on the vehicle rather than one of the transported components. Interestingly, other studies have 
highlighted the potential role of DCV-associated proteins in ASD (Sadakata et al, 2013; 
Paemka et al, 2013; Zhao et al, 2014).  
In addition, as a key element of purine metabolic pathway, MOCOS may indirectly be 
involved in an extensive stimulation of neurotransmitter machinery. Indeed, it is established 
that xanthines and more generally purine derivatives display psychostimulant properties, 
acting at the A1 and A2A subtypes of the adenosine receptors (Lorist and Tops, 2003) but 
also other central receptors as β1/β2-Adrenergic, 5-HT1 serotonin, 5-HT2 serotonin, 
muscarinic, nicotinic, GABA A, Ca2+ channel, in the cortex and the cerebellum (Shi and 
Daly, 1999).  
 Furthermore, an abnormal expression of MOCOS may alter the production and 
functioning of gephyrin, a post-synaptic protein that anchor and cluster GABAA and glycine 
receptors at the membrane (Tyagarajan and Fritschy, 2014). Indeed, in addition to its 
scaffolding role, gephyrin is involved in molybdenum cofactor (MOCO) 
biosynthesis(Fritschy et al, 2008). It can therefore be surmised that a MOCOS-associated 
fluctuation of MOCO alter the synaptic function of gephyrin. Conversely, as recent studies 
have stressed gephyrin as a candidate gene in ASD (for a review, Chen et al, 2014), we may 
postulate that genetic mutations disrupt MOCO synthesis and consequently MOCOS 
expression. It should however be pointed out that no dysregulated trancript expression of 
gephyrin was ever observed in our ASD cohort.   
 Identifying and manipulating downstream effectors of MOCOS will be the next 
critical step to better understand its mechanisms of action. In parallel, we plan to ascertain 
some of its upstream regulators. For example, it is known that the promoter region of 
MOCOS include binding sites for several transcription factors, including GATA3, NRF2 or 
SIRT1, three genes that have been associated to ASD, fragile X syndrome, epilepsy and/or 
oxidative stress (Rout and Clausen, 2009; Napoli et al, 2014; Furnari et al, 2014; Kumari and 
Usdin, 2014). In conclusion, our study opens an unexplored new avenue for the study of 
MOCOS in ASD, and could set bases for the development of new diagnostic tools as well as 
the search of new therapeutics.  
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FIGURE LEGENDS 
 
Figure 1. Human nasal olfactory stem cells reveal a subtle but robust downregulation of 
MOCOS in ASD patients.  
a) Network analysis of differentially expressed genes, in at least 4 ASD patients of the cohort, 
using Ingenuity Pathways Analysis (IPA). Note that TGFB1/WNT catenin are the most 
affected signaling pathways. Solid and dashed lines indicate direct and indirect interactions, 
respectively. Consistently overexpressed or underexpressed genes are in red or blue boxes, 
respectively. Up and down misexpressed genes are in green boxes. b) Volcano plot 
distribution of the microarray data. The blue and red vertical bars indicate magnitude fold-
changes (FC) over 1.5 and the dashed black-line shows the p = 0.05 threshold, with points 
above the line having p < 0.05. Note that the average for all MOCOS probes (10 in total on 
the microarray) display the same pattern of expression. c) Graph depicting MOCOS gene 
expression fold changes in ASD patients, relative to control patients, as detected by 
microarray and RT-qPCR. Note that highly similar results were obtained with both 
techniques. d) Representative pictures showing MOCOS immunostaining of nasal olfactory 
stem cells (OSCs) isolated from one ASD patient (right panel) and his matched healthy 
individual (left panel). Nuclei were counterstained with DAPI. e) Representative Western 
Blot for the detection of MOCOS and GAPDH expression in control and ASD patients. f) 
Quantification of MOCOS expression, expressed as a ratio to GAPDH, in ASD and control 
OSCs using the Western blot technique. Data are represented as mean  SD. * p < 0.05. Scale 
bars: 10 m (d). 
 
 
Figure 2. MOCOS is expressed in various C. elegans and mouse organs including the 
brain. 
a) Sagittal section of an adult mouse brain showing the very high expression of MOCOS in 
the cortex (CTX), the hippocampus (HIP), the outer layers of the cerebellum (CB) and the 
dorsal area of the olfactory bulb (OB). b) Representative picture of MAP2+ neurons (red) in 
the CA1 layer of the hippocampus (dashed white box in a) immunostained for MOCOS 
(green) and counterstained with DAPI. On the right panel, high magnification view. c,d) 
Representative pictures at low (c) and higher magnification (d) of cultivated murine neurons 
immunostained with the indicated antibodies. e,f) Mouse gut sections displaying an intense 
MOCOS staining in ciliated cells (e) and glands (f). g) MOCS1 expression in the developing 
C.elegans was monitored using a mocs-1::GFP transgenic strain. Representative pictures 
showing that MOCS1 was found highly expressed in the intestine and the head in the embryo 
(left panel at the gastrula stage, DIC: differential interference contrast), at larval stages (L1 
on the picture) and maintained throughout adult life. Arrows indicate sheath (white) and 
socket (yellow) glial-like cells, as well as intestinal (red) cells. Scale bars: 100 m (e and f, 
left panels), 20 m (g, middle panels), 10 m (b,c,d; e and f, right panels; g, left panels and 
right panel),   
 
Figure 3. MOCOS expression alterations induce increased stress sensitivity.  
a) Cartoon depicting the main structural characteristics of the gene encoding the 
Molybdenum cofactor sulfurase in plants (A-thaliana), humans and C.elegans. Note the 
sequence homology between the latter two. The nonsense tm3708 mutant lacks intron 1 and 
part of exon 2 while the frameshift ok3439 mutant lacks part of exon 2 and all subsequent 
exons up to exon 5. b) Larval development is slowed down, in a dose-dependent manner, in 
mocs-1 mutants exposed to paraquat. N2 animals were used as wild type controls. mev-1 
worms, a strain hypersensitive to paraquat, was used as an experimental control for the 
paraquat assay. c) Bar chart depicting the reduced survival rate of mocs-1 larval mutants 
exposed to high level of paraquat (4mM). d) Disturbed larval development in eri-1 animals 
fed with an RNAi directed against mocs-1 (R03A10.3) when compared to control eri-1 
worms fed with RNAi against the empty vector L4440. e) Time course survival rate of mocs-
1 adult mutants exposed to high level of paraquat (4 mM). N2 and mev-1 animals were used 
as controls as defined in b). f) Bar chart demonstrating the reduced survival rate of eri-1 adult 
animals fed with an RNAi directed against mocs-1 (R03A10.3) comparatively to their control 
(fed with RNAi against L4440), after exposure to high level of paraquat (4 mM).  g) ASD 
patients’ nasal olfactory stem cells (OSCs) produce higher levels of reactive oxygen species 
(ROS), at baseline and one hour after staurosporine treatment. Data are represented as mean 
 SD. * p < 0.05. n= 80 to 100 animals per group. Experiments were run in triplicate. 
 
Figure 4. MOCOS expression alterations result in neurotransmission and synaptic 
defects.  
a) Paralyzing effects of aldicarb (a cholinesterase inhibitor) in wild type (N2) worms and 
mocs-1 mutants (tm3708, ok3439). ric-3, a strain resistant to aldicarb, was used as an 
experimental control for the aldicarb assay. Note that mocs-1 mutants exhibit a resistance to 
the paralytic effect of aldicarb (n=50-70 animals per group). b,c) Representative pictures (b) 
and quantitative analysis of the mean fluorescence intensity (c) of the YFP-tagged 
neuropeptide NLP-21 in the dorsal cord axons of cholinergic motor neurons for each of the 
indicated C.elegans strains. d) Representative pictures showing the NLP-21 loading in 
neuronal soma (upper row) and coelomocytes (lower row) for each of the indicated strains. e) 
Quantitative analysis of the NLP-21 loading in neuronal soma (upper panel) and 
coelomocytes (lower panel), as measured by mean fluorescent intensity relative to N2 
animals. f) Bar charts depicting the mean area of NLP-21-loaded dense core vesicles (DCVs) 
present in neuronal soma (upper panel) and coelomocytes (lower panel), in mocs-1 mutants 
relative to wild type N2 animals. g) Schematic representation of the TALEN-based strategy 
used to monoallelically invalidate MOCOS in human iPSCs. Half arrows indicate primer sites 
for PCR (P1, P2, P3 and P4). Red triangles indicate the FLPo recognition target (FRT) site.  
h) iPSC-derived neural stem cells were differentiated into neurons and immunostained with 
anti-TUJ1 and anti-SYNAPSIN antibodies. Nuclei were counterstained with DAPI. i,j) 
Representative pictures (i) and quantification (j) of synaptic density in MOCOS+/- NSC-
derived neurons compared to those derived from isogenic control lines (MOCOS+/+). Data are 
represented as mean  SD. * p < 0.05. Scale bars: 100 m (h, left panel); 10 m (b,i); 4 m 
(h, right panels) and 2 m (d). 
 
